within Pharmacolibrary.Drugs.ATC.B;

model B01AF01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019166666666666665,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.04,
    k12             = 8,
    k21             = 8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AF01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rivaroxaban is an oral anticoagulant that acts as a direct Factor Xa inhibitor, used to prevent and treat venous thromboembolism and stroke in patients with atrial fibrillation. It is approved and widely used today for various indications, including prophylaxis of deep vein thrombosis after hip or knee replacement surgery, treatment of deep vein thrombosis and pulmonary embolism, and risk reduction in patients with nonvalvular atrial fibrillation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects, both male and female, under fasting conditions with single oral dose administration.</p><h4>References</h4><ol><li><p>Hindley, B, et al., &amp; Penson, PE (2023). Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 911–923. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2287472&quot;>10.1080/17425255.2023.2287472</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37991392/&quot;>https://pubmed.ncbi.nlm.nih.gov/37991392</a></p></li><li><p>Kreutz, R (2014). Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor. <i>Current clinical pharmacology</i> 9(1) 75–83. DOI:<a href=&quot;https://doi.org/10.2174/1574884708666131111204658&quot;>10.2174/1574884708666131111204658</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24218999/&quot;>https://pubmed.ncbi.nlm.nih.gov/24218999</a></p></li><li><p>Elenjickal, EJ, et al., &amp; Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. <i>American journal of nephrology</i> 55(2) 146–164. DOI:<a href=&quot;https://doi.org/10.1159/000535546&quot;>10.1159/000535546</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38035566/&quot;>https://pubmed.ncbi.nlm.nih.gov/38035566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AF01;
